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Background: Teaching people with epilepsy to identify and manage seizure triggers, implement strategies to
remember to take antiepileptic drugs, implement precautions to minimize risks during seizures, tell others what to
do during a seizure and learn what to do during recovery may lead to better self-management. No teaching
programme exists for adults with epilepsy in the United Kingdom although a number of surveys have shown
patients want more information.
Methods/Design: This is a multicentre, pragmatic, parallel group randomised controlled trial to evaluate the
effectiveness and cost-effectiveness of a two-day Self-Management education for epILEpsy (SMILE (UK)), which was
originally developed in Germany (MOSES).
Four hundred and twenty eight adult patients who attended specialist epilepsy outpatient clinics at 15 NHS participating
sites in the previous 12 months, and who fulfil other eligibility criteria will be randomised to receive the intervention
(SMILE (UK) course with treatment as usual- TAU) or to have TAU only (control). The primary outcome is the effect
on patient reported quality of life (QoL). Secondary outcomes are seizure frequency and psychological distress
(anxiety and depression), perceived impact of epilepsy, adherence to medication, management of adverse effects
from medication, and improved self-efficacy in management (mastery/control) of epilepsy.
Within the trial there will be a nested qualitative study to explore users’ views of the intervention, including
barriers to participation and the perceived benefits of the intervention. The cost-effectiveness of the intervention
will also be assessed.
Discussion: This study will provide quantitative and qualitative evidence of the impact of a structured self management
programme on quality of life and other aspects of clinical and cost effectiveness in adults with poorly controlled epilepsy.
Trial registration: Current Controlled Trials: ISRCTN57937389.
Keywords: Epilepsy, Seizures, Self-management education, Clinical trial, Quality of lifeBackground
Epilepsy is a long-term neurological condition and the
most common serious disorder of the brain [1]. Approxi-
mately 1% of the UK population have diagnosed epilepsy
[2] and following diagnosis, approximately 40% of the pa-
tients will continue to experience two or more seizures
each year [3]. These people are at higher risk of suffering* Correspondence: leone.ridsdale@kcl.ac.uk
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unless otherwise stated.injury, premature death, as well as experiencing psycho-
logical distress and perceived stigmatization due to their
condition [2,4]. Poorly controlled epilepsy is also costly to
society. In the EU, the total cost of epilepsy was estimated
to be €15.5 billion in 2004, the total cost per case was
€2000 - €11500 [5]. One way in which costs to society are
felt is through the costs of providing emergency care to
people with epilepsy (PWE), some of whom attend repeat-
edly [6,7]. Six out of seven admissions for epilepsy are on
an emergency basis [7] and of neurological conditions epi-
lepsy is associated with the highest rate of emergencyral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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important indirect social costs through lost/absent em-
ployment [10].
Coping with life in the context of epilepsy requires
people with epilepsy to become confident with managing
their own condition [10,11]. As well as needing to accept
a potentially stigmatizing diagnosis, they may need to
learn to identify and manage triggers for seizures within
their surroundings, implement strategies to remember
to take a number of antiepileptic drugs (AEDs), imple-
ment precautions to minimize risks due to seizures, tell
others what to do when a seizure occurs and learn what
to do during recovery [12-14].
NHS policy is to empower and support people with
long-term conditions to understand their own needs and
self-manage them [15]. Routine group education pro-
grammes for people with chronic conditions, such as
diabetes and arthritis are already implemented by the
NHS (e.g. DAFNE [16], DESMOND [17]), and there is a
need for a similar programme for people with epilepsy.
A consistent finding in surveys of people with epilepsy is
that they want better provision of information about
how to live with and manage their epilepsy [18-21]. One
survey of patients with poorly controlled epilepsy found
that 1/3rd reported not being told what epilepsy was,
over 90% wanted more information about the disease,
and ~75% felt they had not been given enough informa-
tion about the side effects of antiepileptic drugs (AEDSs)
[18]. Over 60% wanted to talk to someone other than a
consultant about epilepsy. Dawkins and colleagues [22]
found that patients with epilepsy knew no more about
the disorder than those without epilepsy.
Cochrane reviews have identified four educational in-
terventions for people with epilepsy from around the
world [23,24]. None of these interventions had been
tested in the UK, but one of the interventions has been
more robustly evaluated and shows promise for use
in the UK. This programme, developed iteratively in
Germany with the involvement of people with epilepsy
is called ‘Modular Service Package Epilepsy’ (MOSES)
[25,26]. The original randomised controlled trial of MOSES
included people with poorly controlled epilepsy, 72% of
whom had more than 12 seizures in the previous six
months. The reported benefits of MOSES included im-
proved knowledge about epilepsy, better seizure control
and coping and greater tolerance of and fewer reported
AED side effects.
MOSES has been developed and trialled in Germany,
Austria and Switzerland and translated into English [27].
With input from British Epilepsy Association, we have
modified it for use in the UK, and will employ a rando-
mised controlled trial to test whether it affects quality of
life, clinical outcomes and cost effectiveness of health
service use compared to treatment as usual (TAU).Advisors from Epilepsy Action contributed to the de-
sign of the intervention, helping to identify appropriate
outcome measures and directing us to adopt a waiting
list control design.
Objective
SMILE (UK) is a complex intervention [28] with a range
of training modules. We have identified three main
knowledge gaps which we plan to address in the rando-
mised controlled trial:
1) the acceptability and appropriateness of its format in
an outpatient UK NHS setting;
2) its effectiveness in improving QoL for people with
poorly controlled epilepsy;
3) its cost-effectiveness.
Methods and design
Trial design
This is a multicentre pragmatic parallel group randomised
controlled trial with 1:1 randomisation (intervention:
control). The patients are followed up for 12 months.
Trial settings
The trial will take place in London and other parts of
South-East England. We have recruited 15 NHS neurol-
ogists who specialise in epilepsy and whose clinic lists
will be used to identify potential study participants.
Target population
We plan to recruit adults with epilepsy aged 16 years and
over who attended neurology outpatient appointments in the
previous 12 months, and who satisfy study eligibility criteria.
Inclusion criteria:
 Have a documented diagnosis of epilepsy (all
epilepsy syndromes and seizures types permitted)
 Are currently being prescribed AEDs
 Are aged ≥16 years (no upper age limit)
 Are able to provide informed consent, participate
in the workshops and complete the questionnaires
in English
 Have had at least 2 seizures in previous 12 months
(as reported by patient)
Exclusion criteria:
 Have actual/suspected psychogenic non-epileptic
seizures only
 Have acute symptomatic seizures related to acute
neurological illness or substance misuse
 Have a severe psychiatric disorder (e.g., psychosis)
or terminal medical condition
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Participant recruitment
Patients attending neurology outpatient clinics within
the preceding 12 months will be identified by Local
Investigators (neurologists) from electronic medical re-
cords at the participating NHS Trusts.
Each patient will receive a letter from the consultant
neurologist responsible for their medical care. This letter
will inform patients of the study and give them an op-
portunity to opt-out of the next step, the screening
of their medical records to evaluate eligibility criteria,
within three weeks.
Following completion of medical records screening at
each study site, the patients identified as potentially eli-
gible will be sent a second letter from the consultant, in-
viting them to take part. Patients who are not interested
in participating are asked to return the opt-out reply slip
within three weeks of the receipt of the invitation. Pa-
tients who do not opt-out at this stage will be contacted
by phone by one of the research workers.
This telephone call is an opportunity to further explain
the study, confirm eligibility and to arrange an appoint-
ment for obtaining consent and collecting data for base-
line (pre-randomisation) measures. The participants are
provided with a patient information sheet and a free post
envelope with each of the letters.
Over the course of the study the participants are re-
quired to complete three sets of questionnaires (Table 1)
either in a face-to-face interview with a research worker
(at baseline and at 12-month follow-up) or through pos-
tal return of the completed questionnaire (at 6-month
follow-up). In order to encourage continued participa-
tion in the study we will offer each participant a £20Table 1 Outcome measures and data collection
Outcome variables Measures
Primary outcome
Quality of life QOLIE-31-P [29]
Secondary outcomes
Seizure frequency Two scales [30,31]
Seizure recency Patient reported date of last seizure
Impact of epilepsy Impact of epilepsy scale [32]
Medication adherence Epilepsy Self Management Scale [33]
Medication adverse effects QOLIE-31-P [29]
Psychological distress Hospital Anxiety and Depression scale [3
Perceived stigma Stigma of Epilepsy Scale [36]
Mastery/control of epilepsy Epilepsy-specific scale [37]
Health economics Client Service Receipt Inventory [38] and
*RW = research worker collected data (in a face to face interview with a participant)
**SR = self reported data (questionnaires completed by the participant and postedvoucher upon completion of the 12 month questionnaire
(end of follow-up period).
The participants and data flow in the study are shown
in Figure 1.Consent
The research workers will visit potential participants at
their home, or at a place of their choice and explain the
study in detail. Those who agree to participate and
satisfy eligibility criteria will sign the consent form and
complete a set of questionnaires before being randomised.Intervention
The intervention is a group-based, interactive course. It
is delivered by two health professionals (educational fa-
cilitators, EFs) to groups of 8–12 participants (who may
include carers of PWE attending the group). The inter-
vention consists of interactive discussion, presentation
slides, the use of flip-charts and a workbook. The work-
book serves as a source of information and provides
space for note-taking and exercises completed during the
sessions. There are nine modules in the course: 1. Living
with epilepsy; 2. People with epilepsy; 3. Basic knowledge
about seizures; 4. Diagnosis; 5. Treatment; 6. Self control;
7. Prognosis ; 8. Personal and social life; 9. Network epi-
lepsy. Delivery of all the modules takes approximately
16 hours over two consecutive days.
The courses will be delivered at the participating NHS
sites. Attendance of the course and any interruptions
(e.g. due to seizures) will be monitored, and reported
through treatment attendance logs. EFs will record infor-
mation about seizures that occur at the time of treatment,
because they may impact on how much treatment the
patient received during the two day course.No. items T0 T1 T2
39 RW* SR** RW
2 RW SR RW
1 RW SR RW
9 RW SR RW
10 RW RW
2 RW RW
4,35] 14 RW RW
3 RW RW
6 RW RW
EQ-5D [39] 13 RW RW
.
to the research team).
Figure 1 Study flow diagram.
Kralj-Hans et al. BMC Neurology 2014, 14:69 Page 4 of 8
http://www.biomedcentral.com/1471-2377/14/69SMILE (UK) courses will be offered to those rando-
mised to the control group (TAU) once all the follow-up
data has been collected.
Educational facilitators
The courses will be delivered by teams of two EFs who
are NHS-employed healthcare professionals (epilepsy
nurse specialists or clinical physiologists). They (n = 12)
underwent a standardised two-day training course deliv-
ered by a team of MOSES specialists from Germany (see
Acknowledgements). Four of the health professionals who
received the training then delivered two sessions of SMILE
(UK) courses to patients with epilepsy who volunteered to
take part in the pilot study (through Epilepsy Action). Based
on the feedback from the volunteers and from observers of
the pilot courses, the research team provided review semi-
nars to all the trained EFs to re-enforce the skills and strat-
egies necessary for successful delivery of the courses.
Treatment fidelity
A checklist of treatment components based on the fina-
lised course structure and content will be devised following
consensus among lead co-investigators in this area. A rat-
ing scale will be developed and piloted on four randomly-selected courses to assess variability across raters, clarify
the meaning of individual items, and improve coding rules
and future inter-observer reliability.
With the permission of the participants, all SMILE
(UK) courses will be audio-recorded to enable two inde-
pendent researchers to identify the presence of treat-
ment components within the course and to determine
whether specific modules were appropriately delivered.
The aim is for two researchers to rate 25% of course
sessions independently.
Courses for treatment integrity rating will be selected
randomly (using computer generated numbers) stratified
by the EF teams and by the time they took place (early,
late or in the middle of the trial). The EFs will not be
informed about which sessions will be selected for rating.
Outcomes and outcome measures
Primary outcome
The primary objective of the SMILE (UK) trial is to
assess whether participation in the course leads to a
change in QoL score in people with poorly controlled
epilepsy. This outcome will be measured using the
‘Quality of Life In Epilepsy 31 P’ scale (QOLIE-31-P)
[29]. This questionnaire will be completed by the partici-
pants prior to randomisation (2–3 weeks) and at 12 months
following randomisation in a face-to-face interaction with
a research worker. At 6 months post randomisation, the
questionnaire will be mailed to participants for completion.
Secondary outcomes
Secondary objectives are to assess whether SMILE (UK)
course participation leads to: reductions in seizure fre-
quency and psychological distress (anxiety and depres-
sion), and improvements in perceived impact of epilepsy,
adherence to medication, management of adverse effects
from medication, and self efficacy in management (mas-
tery/control) of epilepsy, and whether it is cost-effective.
All the outcomes will be measured using the instru-
ments shown in Table 1. Completion of the question-
naires is estimated to take about one hour of the
patient’s time.
At 6 months after randomisation a subset of instru-
ments will be posted to the participants for completion
on their own. To encourage return of completed ques-
tionnaires a phone call to the participant will be sched-
uled approximately a week after posting them.
Other data
Demographic information (age, sex, ethnicity, educational
background, living arrangements, marital status) will be
collected prior to randomisation as part of a face-to-face
interview with a research worker. Details regarding any
newly diagnosed conditions or symptoms experienced by
the study participants since randomisation, which may be
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12 months post-randomisation.
Sample size calculations
The sample size calculation was based on the primary
outcome measure, QoL. The primary intention-to-treat
(ITT) analyses will compare two equally-sized treatment
arms, treatment and control, on the QOLIE-31-P scale
at 12 months. An overall sample size of N = 320 (rando-
mised 1:1) provides 91.3% power to detect an effect size
of d = 0.4 on the QOLIE-31-P using an analysis of co-
variance with 2-sided 5% significance tests. This calcula-
tion is based on the conservative assumption of a zero
correlation between baseline and post treatment scores
on QOLIE-31-P. An effect size of d = 0.4 corresponds to
a change of around 6–7 points on the overall QoL score.
Since the active treatment is a group treatment, deliv-
ered by different therapists within sites, we will allow for
standard error inflation due to training group effects.
We estimate that attrition rate at 1 year will be around
25%. Therefore, to ensure adequate and equally sized
groups an initial sample of N = 428 patients is required
(n = 320/0.75; 214 patients per arm).
Randomisation and concealment
Randomisation will be carried out remotely by the King’s
Clinical Trials Unit (KCTU) at the Institute of Psychiatry
(www.ctu.co.uk) following consent and completion of
the baseline data collection. The unit of randomisation
will be the individual participant and randomisation will
be in 1:1 ratio between the intervention and the control
group, stratified by the location of epilepsy clinics from
which the patients were recruited. The results of the
allocation will be concealed from the trial statistician
and the research workers responsible for consent and
data collection. The trial manager receives notification
of outcomes of randomisation.
Statistical analyses
The objective of the statistical analyses is the evaluation
of the effectiveness of the SMILE intervention. The ITT
approach, which analyses patients in the groups to which
they were randomised irrespective of their treatment
compliance, will be used throughout to estimate effect-
iveness. Confounding bias and systematic measurement
error will be avoided by the use of randomisation and
blinding of outcome assessors respectively.
Linear mixed modelling (LMM) will be employed to
estimate the primary outcome difference between the trial
arms (effectiveness). Models will contain the following
fixed effects: the group difference of interest - modelled by
an effect of intervention arm, time (6 m or 12 m) and an
interaction term - and dummy variables representing the
randomisation stratifier (up to 15 treatment centres). Toaccount for correlations between repeated measures on
the same individual, a subject-varying random intercept
will be included. To allow for correlations between at-
tendees of the same course group a further random effect
that varies with training group will be allowed for within
the intervention arm. Treatment effects on secondary out-
comes will be assessed similarly, using generalisations of
the linear mixed model to allow for non-normal data
where necessary (e.g. time elapsed since last seizure or
seizure frequency).
There will be missing data in post treatment outcome
variables where participants are lost to follow-up. The
LMM analyses are based on maximum likelihood and
resulting inferences are valid provided the missing data
generating mechanism is missing at random (MAR). We
will empirically assess whether any baseline variables
(e.g. age, gender, age when epilepsy diagnosed) predict
missingness and if so, we would condition on such vari-
ables by including them in the statistical model. We will
also assess whether missingness is related to post treat-
ment variables (e.g. other outcomes and most notably
non-compliance with the intervention). Should this be
the case we will use multiple imputation to generate
inferences that are valid under this type of MAR [40].
However, since any analysis will only be valid under
MAR and not if the data generating process is inform-
ative, a formal sensitivity analysis [41] will assess the
impact on the treatment effect estimate of any likely
departures from MAR.
If there is considerable non-compliance with the
SMILE (UK) training programme we will carry out fur-
ther explanatory analyses to assess the efficacy of the
treatment. Specifically, we will employ instrumental vari-
able methods to evaluate the causal effect of receiving
the intervention in the subpopulations of participants
who would receive a ‘high dose’ or a ‘high quality’ version
of intervention if offered. We call this subpopulation the
“compliers” and will evaluate efficacy by estimating the
complier average causal effect of the intervention. We
expect the randomisation itself to serve as a strong
instrumental variable for this purpose [42].
Cost-effectiveness analysis
Intervention costs will be estimated based on staff time
required for training, supervision and delivery, overheads
and capital costs combined with attendance data to esti-
mate the cost per participant. Other costs will be calcu-
lated by combining service use data with unit cost
information [43]. Lost employment costs will be calcu-
lated by combining lost work days with average wage
rates. Health care costs and societal (including informal
care and lost employment) costs will be compared be-
tween the two arms. Cost data are usually skewed and
we will use bootstrap methods to produce 95% confidence
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will be assessed using health care and societal perspectives
by combining the costs with data on the primary outcome
measure at 12 months. Cost-utility will be measured by
combining costs with quality-adjusted life years (QALYs),
derived from the European Quality of Life-5 Dimensions
(EQ-5D) questionnaire. If the intervention results in better
outcomes and lower costs, then it will be ‘dominant’. If,
though, it results in better outcomes but higher costs,
then incremental cost-effectiveness ratios will be calcu-
lated which will indicate the extra cost incurred to achieve
a one-unit improvement on the QOLIE or one extra
QALY (both at 12 months). To address the uncertainty
around these estimates 1000 cost-outcome combinations
will be produced using bootstrap methods and plotted on
a cost-effectiveness plane. Cost-effectiveness will also be
interpreted using cost-effectiveness acceptability curves,
which will show the probability that the intervention is
the most cost-effective option for a range of different
values placed on an improvement in outcome. The range
of values for QALYs will be £0 to £100,000; this includes
the threshold that appears to be used by the U.K.’s
National Institute for Health and Clinical Excellence
when judging the cost-effectiveness of a health tech-
nology. The range for improvements on the QOLIE
will be chosen such that values at which the intervention
or TAU has a 50% and 70% and 90% likelihood of being
cost-effective are identified.
Nested qualitative study
Individual in-depth interviews will be conducted with 20
study participants who were randomised to SMILE (UK)
intervention and their main supporter(s) with whom they
have regular contact. Purposive sampling will include par-
ticipants who completed the trial and those who did not,
and carers who attended SMILE (UK) sessions. We will
aim to ensure that the sample represents differences in
gender, age, ethnicity and severity of seizures as recorded
at the beginning of the trial.
Interviews will take place at selected participants’ homes
or a convenient public place if preferred. In a guided con-
versation participants will be asked to describe their expe-
riences in taking part in the courses, their perceptions of
things they valued and found of particular benefit for
them as well as negative aspects, and will also discuss any
factors that encouraged or hindered their participation in
the courses, and whether and in what ways they have con-
tinued to make use of the training received. The content
of the course workbook will also be discussed in relation
to participants’ own needs and lifestyles.
The interviews will be audio-recorded, transcribed and
textual coding undertaken. The lower level codes will
be grouped into themes and analysis undertaken through a
process of constant comparison, with particular attentiongiven to the analysis and explanation of variations between
respondents and the views of study participants and carers.
Two members of the research team will participate in data
analysis to reduce bias in the identification and interpret-
ation of themes.
Monitoring
Monitoring of this trial by the Trial Steering (TSC) and
Data Monitoring Committees (DMEC) will help to ensure
that the objectives of the trial are reached as planned.
Compliance with Good Clinical Practice and scientific
integrity will be managed by the study management
team (includes co-investigators, trial manager and KCTU)
through regular and ad-hoc meetings. The KCTU will
provide regular reports on data quality to ensure the in-
tegrity of randomisation, to monitor the level of missing
data and the timeliness of data entry and check for il-
logical or inconsistent data. Data collection procedures
will be monitored and source data verification against
the paper data collection forms undertaken at regular
intervals.
Discussion
This is the first randomized controlled trial of self-
management education for adults with poorly controlled
epilepsy in the UK. The intervention has been adapted for
use within the NHS and the study aims to provide qualita-
tive and quantitative evidence of the impact of a complex
intervention on patients in terms of its clinical and cost
effectiveness.
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